Unknown

Dataset Information

0

Antibody response to 2- and 3-dose SARS-CoV-2 mRNA vaccination in pediatric and adolescent kidney transplant recipients.


ABSTRACT:

Background

Additional "booster" doses of mRNA SARS-CoV-2 vaccines have become standard of care for immunosuppressed patients, including kidney transplant recipients (KTR). While these additional doses have been shown to be efficacious in the adult KTR population, there is paucity of data for pediatric and adolescent KTR.

Methods

We conducted a retrospective single-center observational study to determine the proportion of pediatric and adolescent KTR who seroconverted following two- and three-dose regimens of an mRNA SARS-CoV-2 vaccine series.

Results

Forty-three pediatric and adolescent KTR at our center received at least two doses of an mRNA SARS-CoV-2 vaccine. Seroconversion was noted in 56% of those who received a 2-dose series and increased to 85% in those who received a third dose. In the 16 patients who did not seroconvert after a two-dose series, 12 (75%) seroconverted following the third dose. No serious adverse effects of immunization were noted.

Conclusions

Our results demonstrate that additional SARS-CoV-2 vaccine doses are not only safe and efficacious in pediatric and adolescent KTR, but may be necessary to optimize antibody response. A higher resolution version of the Graphical abstract is available as Supplementary information.

SUBMITTER: Crane C 

PROVIDER: S-EPMC9244318 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9281214 | biostudies-literature
| S-EPMC8091803 | biostudies-literature
| S-EPMC9553374 | biostudies-literature
| S-EPMC8475856 | biostudies-literature
| S-EPMC3772511 | biostudies-literature
| S-EPMC10485855 | biostudies-literature
| S-EPMC8436382 | biostudies-literature
| S-EPMC6590112 | biostudies-literature
| S-EPMC8602732 | biostudies-literature